Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting, 36825-36826 [2024-09591]

Download as PDF Federal Register / Vol. 89, No. 87 / Friday, May 3, 2024 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings lotter on DSK11XQN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Epidemiology Cohorts (U01). Date: June 4, 2024. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W110, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Priya Srinivasan, Ph.D., Scientific Review Officer, Resource and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W110, Rockville, Maryland 20850, 240–276–5619, priya.srinivasan@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–12: NCI Clinical and Translational Cancer Research. Date: June 14, 2024. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W526, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Viktoriya Sidorenko, Ph.D., Scientific Review Officer, Program and Review Extramural Staff Training Office, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W526, Rockville, Maryland 20850, 240–276–5073, viktoriya.sidorenko@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review SEP–C. Date: June 17–18, 2024 Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W634, Rockville, Maryland 20850 (Virtual Meeting). VerDate Sep<11>2014 18:11 May 02, 2024 Jkt 262001 Contact Person: Michael E. Lindquist, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W634, Rockville, Maryland 20850, mike.lindquist@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–6: NCI Clinical and Translational Cancer Research. Date: June 21, 2024. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W260, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Robert F. Gahl, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9606 Medical Center Drive, Room 7W260, Rockville, Maryland 20850, 240–276–7869, robert.gahl@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–8: NCI Clinical and Translational Cancer Research. Date: June 25, 2024. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W110, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Priya Srinivasan, Ph.D., Scientific Review Officer, Resource and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W110, Rockville, Maryland 20850, 240–276–5619, priya.srinivasan@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 29, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–09639 Filed 5–2–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting AGENCY: National Institutes of Health, HHS. ACTION: PO 00000 Notice. Frm 00077 Fmt 4703 Sfmt 4703 36825 The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on May 30, 2024. The topic for this meeting will be ‘‘Artificial Intelligence in Diabetes Precision Medicine: Real world data, real world opportunities and challenges’’. The meeting is open to the public. DATES: The meeting will be held on May 30, 2024 from 12:00 p.m. to 3:30 p.m. EDT. ADDRESSES: The meeting will be held via the Zoom online video conferencing platform. For details, and to register, please contact dmicc@mail.nih.gov. FOR FURTHER INFORMATION CONTACT: For further information concerning this meeting, including a draft agenda, which will be posted when available, see the DMICC website, https:// www.niddk.nih.gov/about-niddk/ advisory-coordinating-committees/ diabetes-mellitus-interagencycoordinating-committeedmicc?dkrd=lgdmn0022, or contact Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, Bethesda, MD 20892, telephone: 301– 435–1011; email: dmicc@mail.nih.gov. SUPPLEMENTARY INFORMATION: In accordance with 42 U.S. Code 285c–3, the DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The May 30, 2024 DMICC meeting will focus on ‘‘Artificial Intelligence in Diabetes Precision Medicine: Real world data, real world opportunities and challenges.’’ Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives or organizations should submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the SUMMARY: E:\FR\FM\03MYN1.SGM 03MYN1 36826 Federal Register / Vol. 89, No. 87 / Friday, May 3, 2024 / Notices meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, oral comments will be allowed on a first-come, first-serve basis. Members of the public who would like to receive email notification about future DMICC meetings should register for the listserv available on the DMICC website, https://www.niddk.nih.gov/ about-niddk/advisory-coordinatingcommittees/diabetes-mellitusinteragency-coordinating-committeedmicc?dkrd=lgdmn0022. William T. Cefalu, Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and Metabolic Diseases, National Institutes of Health. [FR Doc. 2024–09591 Filed 5–2–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health lotter on DSK11XQN23PROD with NOTICES1 National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Analytical Chemistry and Stability Testing of Treatment Drugs for Substance Use Disorders. Date: June 6, 2024. VerDate Sep<11>2014 18:11 May 02, 2024 Jkt 262001 Time: 2:00 p.m. to 3:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443–4577, sudhirkumar.yanpallewar@ nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Seeking Products to Address Social Needs Impacting Substance Use Disorders (SUD). Date: June 10, 2024. Time: 9:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827–5702, sindhu.kizhakkemadathil@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: April 29, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–09640 Filed 5–2–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Library of Medicine; Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Literature Selection Technical Review Committee. The meeting will be open to the public as indicated below. Individuals who plan to attend as well as those who need special assistance, such as sign language interpretation or other reasonable accommodations, must notify the Contact Person listed below in advance of the meeting. The open PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). The meeting is devoted to the review and evaluation of journals for potential indexing by the National Library of Medicine and will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended. Premature disclosure of the titles of the journals as potential titles to be indexed by the National Library of Medicine, the discussions, and the presence of individuals associated with these publications could significantly frustrate the review and evaluation of individual journals. Name of Committee: Literature Selection Technical Review Committee. Date: June 27–28, 2024. Closed: June 27, 2024, 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine. Place: National Library of Medicine, Building 38, Room 4S412, 8600 Rockville Pike, Bethesda, MD 20892 (In-Person Meeting). Closed: June 28, 2024, 8:30 a.m. to 9:15 a.m. Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine. Place: National Library of Medicine, Building 38, Room 4S412, 8600 Rockville Pike, Bethesda, MD 20892 (In-Person Meeting). Contact Person: Dianne Babski, Associate Director, Division of Library Operations, National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, 301–827–4279, babskid@mail.nih.gov. Open: June 28, 2024, 9:15 a.m. to 10:30 a.m. Agenda: NLM Directors’ Report. Place: National Library of Medicine, Building 38, Room 4S412, 8600 Rockville Pike, Bethesda, MD 20892 (In-Person Meeting). Closed: June 28, 2024, 10:30 a.m. to 3:00 p.m. Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine. Place: National Library of Medicine, Building 38, Room 4S412, 8600 Rockville Pike, Bethesda, MD 20892 (In-Person Meeting). In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice at least 10 days in advance of the meeting. Information is also available on the Institute’s/Center’s home page: https:// www.nlm.nih.gov/medline/medline_about_ lstrc.html, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library E:\FR\FM\03MYN1.SGM 03MYN1

Agencies

[Federal Register Volume 89, Number 87 (Friday, May 3, 2024)]
[Notices]
[Pages 36825-36826]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09591]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Diabetes Mellitus Interagency Coordinating Committee 
Meeting

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee 
(DMICC) will hold a meeting on May 30, 2024. The topic for this meeting 
will be ``Artificial Intelligence in Diabetes Precision Medicine: Real 
world data, real world opportunities and challenges''. The meeting is 
open to the public.

DATES: The meeting will be held on May 30, 2024 from 12:00 p.m. to 3:30 
p.m. EDT.

ADDRESSES: The meeting will be held via the Zoom online video 
conferencing platform. For details, and to register, please contact 
[email protected].

FOR FURTHER INFORMATION CONTACT: For further information concerning 
this meeting, including a draft agenda, which will be posted when 
available, see the DMICC website, https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022, or contact Dr. William 
Cefalu, Executive Secretary of the Diabetes Mellitus Interagency 
Coordinating Committee, National Institute of Diabetes and Digestive 
and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, 
Bethesda, MD 20892, telephone: 301-435-1011; email: [email protected].

SUPPLEMENTARY INFORMATION: In accordance with 42 U.S. Code 285c-3, the 
DMICC, chaired by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) comprising members of the Department of Health 
and Human Services and other federal agencies that support diabetes-
related activities, facilitates cooperation, communication, and 
collaboration on diabetes among government entities. DMICC meetings, 
held several times a year, provide an opportunity for Committee members 
to learn about and discuss current and future diabetes programs in 
DMICC member organizations and to identify opportunities for 
collaboration. The May 30, 2024 DMICC meeting will focus on 
``Artificial Intelligence in Diabetes Precision Medicine: Real world 
data, real world opportunities and challenges.''
    Any member of the public interested in presenting oral comments to 
the Committee should notify the contact person listed on this notice at 
least 5 days in advance of the meeting. Interested individuals and 
representatives or organizations should submit a letter of intent, a 
brief description of the organization represented, and a written copy 
of their oral presentation in advance of the

[[Page 36826]]

meeting. Only one representative of an organization will be allowed to 
present; oral comments and presentations will be limited to a maximum 
of 5 minutes. Printed and electronic copies are requested for the 
record. In addition, any interested person may file written comments 
with the Committee by forwarding their statement to the contact person 
listed on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person. Because of time constraints for 
the meeting, oral comments will be allowed on a first-come, first-serve 
basis.
    Members of the public who would like to receive email notification 
about future DMICC meetings should register for the listserv available 
on the DMICC website, https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022.

William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, 
National Institute of Diabetes and Digestive and Kidney Diseases, and 
Metabolic Diseases, National Institutes of Health.
[FR Doc. 2024-09591 Filed 5-2-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.